.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,713,464

« Back to Dashboard

Details for Patent: 6,713,464

Title: Derivatives of 3,3-diphenylpropylamines
Abstract:The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
Inventor(s): Meese; Claus (Monheim, DE), Sparf; Bengt (Trangsund, SE)
Assignee: Schwarz Pharma AG (Monheim, DE)
Filing Date:Jan 02, 2001
Application Number:09/700,094
Claims:1. A 3,3-Diphenylpropylamine of the general formula I: ##STR52## wherein R and R' are independently a) hydrogen; or b) formyl, C.sub.1 -C.sub.6 alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstitited arylcarbonyl; with the proviso that R' is not hydrogen, methyl or benzyl when R is hydrogen, and R is not ethyl when R' is hydrogen, X represents a tertiary amino group of formula Ia ##STR53## wherein R.sup.8 and R.sup.9 represent C.sub.1 -C.sub.6 alkyl groups, which may be the same or different and which together contain at least three carbon atoms, or R.sup.8 and R.sup.9 may form a ring together with the amine nitrogen, A represents hydrogen (.sup.1 H) or deuterium (.sup.2 H), and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

2. The 3,3-Diphenylpropylamine as claimed in claim 1, wherein X is ##STR54##

3. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from phenolic monoesters represented by the general formula II ##STR55## wherein R.sup.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl.

4. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from: (.+-.)-formic acid 2-(3diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-n-butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-2,2methylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-cyclopentanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-cyclohexanecarboxylic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-4-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-2-methylbenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)hydroxymethylphenyl ester, (.+-.)-2-acetoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-1-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-2-naphthoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-4-chlorobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-4-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-2-methoxybenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, (.+-.)-4-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, and (.+-.)-2-nitrobenzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester.

5. The 3,3-Diphenylpropylamine as claimed in claim 2 represented by the general formula III ##STR56## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl.

6. The 3,3-Diphenylpropylamine as claimed in claim 5 selected from: (.+-.)-formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, (.+-.)-acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, (.+-.)-propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-propionyloxymethylphenyl ester, (.+-.)-n-butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (.+-.)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl ester, (.+-.)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester, (.+-.)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, R-(+)-benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (.+-.)-pent-4-enoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-(pent-4-enoyloxymethyl)-phenyl ester, cyclic oct-4-ene-1,8-dioate of Intermediate B, cyclic octane-1,8-dioate of Intermediate B, and poly-co-DL-lactides of Intermediate B, said Intermediate B having the formula ##STR57##

7. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from mixed diesters represented by the general formula IV ##STR58## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl, and R.sup.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl with the proviso that R.sup.1 and R.sup.2 are not identical.

8. The 3,3-Diphenylpropylamine as claimed in claim 7 selected from: (.+-.)-acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, (.+-.)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester, (.+-.)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester, R-(+)-benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-acetoxymethylphenyl ester, (.+-.)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, R-(+)-isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, (.+-.)-2,2-dimethylpropionic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester, (.+-.)-2,2-dimethylpropionic acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester, and (.+-.)-benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester.

9. The 3,3-Diphenylpropylamine as claimed in claim 2 selected from benzylic monoesters represented by the general formula V ##STR59## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl.

10. The 3,3-Diphenylpropylamine as claimed in claim 9 selected from: (.+-.)-formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, (.+-.)-acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, (.+-.)-propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, (.+-.)-butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, (.+-.)-isobutyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, (.+-.)-2,2-dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester, and (.+-.)-benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester.

11. A 3,3-Diphenylpropylamine selected from (i) compounds of the formulae IX and IX' ##STR60## wherein o and p are the same or different and range from 0 to 6, (ii) Poly-co-DL-lactides of 2-(3-diisopropylamino-phenylpropyl)-4-hydroxymethylphenol and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

12. A process for the production of phenolic monoesters according to claim 3, which comprises treatment of a compound of the formula ##STR61## with an equivalent of an acylating agent of formula ##STR62## wherein LG represents a leaving group selected from halide, carboxylate and imidazolide in an inert solvent in the presence of a condensing agent.

13. A process for the production of identical diesters according to claim 5, which comprises treatment of a compound of the formula ##STR63## with at least two equivalents of the acylating agent of formula ##STR64## wherein LG represents a leaving group selected from halide, carboxylate and imidazolide in an inert solvent in the presence of a condensing agent.

14. A process for the preparation of benzylic monoesters according to claim 9, which comprises treatment of a compound of the formula ##STR65## at room temperature and under anhydrous conditions with activated esters in the presence of enzymes selected from lipases or esterases.

15. A process for the preparation of mixed diesters according to claim 7, which comprises acylation of a benzylic monoester represented by the general formula V ##STR66## or of a phenolic monoester represented by the formula II ##STR67##

16. A 3,3-Diphenylpropylamine of the general formula VII': ##STR68## wherein R is a) hydrogen; or b) formyl, C.sub.1 -C.sub.6 alkylcarbonyl, cycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl; X represents a tertiary amino group of formula Ia ##STR69## wherein R.sup.8 and R.sup.9 represent non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R.sup.8 and R.sup.9 may form a ring together with the amine nitrogen, Y and Z independently represent a single bond between the (CH.sub.2).sub.n group and the carbonyl group, O, S or NH, A represents hydrogen (.sup.1 H) or deuterium (.sup.2 H), n is 0 to 12, and

their salts with physiologically acceptable acids, their free bases and, when the compounds are in the form of optical isomers, the racemic mixture and the individual enantiomers.

17. The 3,3-Diphenylpropylamines as claimed in claim 16, wherein X is ##STR70##

18. The 3,3-Diphenylpropylamine as claimed in claim 17, selected from phenolic monoesters represented by the general formula II' ##STR71##

19. A process for the production of phenolic monoesters according to claim 18, which comprises treatment of two equivalents of a compound of the formula ##STR72## with an acylating agent of formula ##STR73## wherein Hal represents a halogen atom.

20. A pharmaceutical composition comprising a 3,3-diphenylpropylamine according to any one of claims 1-10, 11 and 16-18 and a pharmaceutically acceptable carrier.

21. A method of antagonizing a muscarinic receptor, the method comprising contacting the receptor with a compound according to any one of claims 1-10, 11 and 16-18.

22. A method of treating a disease in a mammal that is amenable to treatment by antagonizing muscarinic receptors in the mammal, the method comprising administering an amount of a composition according to claim 20 effective to diminish or eliminate symptoms of the disease.

23. The method according to claim 22 wherein the disease is urinary incontinence.

24. The method according to claim 23 wherein the mammal is a human.

25. A 3,3-Diphenylpropylamine selected from: (.+-.)-malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl]ester, (.+-.)-succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, (.+-.)-pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl]ester, and (.+-.)-hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl]ester.

26. The 3,3-Diphenylpropylamine of claim 2, wherein the 3,3-Diphenylpropylamine is R-(+)-isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc